|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.54/0.87
|
企業價值
786.30M
|
資產負債 |
每股賬面淨值
2.61
|
現金流量 |
現金流量率
--
|
損益表 |
收益
175.51M
|
每股收益
1.10
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/04/28 21:38 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States. |